HTB November/December 2022 (16 December 2022)
16 December 2022. Related: Editorial.
2022
In memory: Giulio Maria CorbellI and Chris Sandford
1 December 2022. Related: In memory.
Latest statistics on HIV in the UK: data for 2021
1 December 2022. Related: Special reports, HIV prevention and transmission.
Glasgow HIV Congress 2022
1 December 2022. Related: Conference reports.
Glasgow 2022: Better re-suppression after viral rebound with DTG-based ART compared to EFV- or PI-based regimens
1 December 2022. Related: Conference reports, Treatment strategies.
Glasgow 2022: Vertical transmission rate below 0.3% among women living with HIV in the UK
1 December 2022. Related: Conference reports, Pregnancy.
Glasgow 2022: Impact of islatravir on lymphocyte counts in a dose-ranging study: a post-hoc analysis
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Islatravir studies to use 0.25 mg daily dose to overcome risk of reducing CD4 and total lymphocytes
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Fostemsavir 240 week results from BRIGHTE study
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Fostemsavir: QT prolongation and drug-drug interactions
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Mpox updates on epidemiology, treatment and prevention
1 December 2022. Related: Conference reports, mpox (monkeypox).
24th International AIDS Conference (AIDS 2022): Final report
1 December 2022. Related: Conference reports.
IAS 2022: Metabolic complications of newer HIV drugs in older people
1 December 2022. Related: Conference reports, Lipodystrophy and metabolic complications.
Cabotegravir-LA submitted to EMA for use as PrEP in Europe
1 December 2022. Related: HIV prevention and transmission.
CHAI 2022 report on global access to ART
1 December 2022. Related: Treatment access.
Early HIV diagnosis and treatment are important for better long-term health
1 December 2022. Related: Antiretrovirals.
EU recommends approval of dispersible abacavir/lamivudine/dolutegravir FDC for children weighing 14 to >25 kg
1 December 2022. Related: Antiretrovirals, Paediatric care.
BHIVA 2022 ART guidelines: online with non-technical summary
1 December 2022. Related: Guidelines.
National HIV prescribing for England 2022: algorithms and policies
1 December 2022. Related: Guidelines.
EACS Guidelines update (2022)
1 December 2022. Related: Guidelines.
IAS–USA Guidelines on HIV Treatment and Prevention (2022)
1 December 2022. Related: Guidelines.
HTB: no. 11/12 (November/December 2022) PDF download
1 December 2022. Related: PDFs.
HTB October 2022 (3 October 2022)
3 October 2022. Related: Editorial.
Monkeypox into Autumn: still no emergency funding, vaccine efficacy and UK declines further vaccines
3 October 2022. Related: Special reports, mpox (monkeypox).
BHIVA General Medicine Course 2022
3 October 2022. Related: Future meetings.
14th International Workshop on HIV & Pediatrics
3 October 2022. Related: Conference reports.
Switch study for people with insomnia using dolutegravir: still enrolling
3 October 2022. Related: Research studies.
First paediatric pharmacokinetic data of dolutegravir in combination with a TAF-based NRTI backbone
3 October 2022. Related: Conference reports, Paediatric care.
24th International AIDS Conference (AIDS 2022): further reports
3 October 2022. Related: Conference reports.
AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3
3 October 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
AIDS 2022: Gender-affirming hormones, weight gain and ART
3 October 2022. Related: Conference reports, PK and drug interactions, Side effects.
Islatravir update: treatment studies to use a lower dose but PrEP research discontinued in favour of MK-8537
3 October 2022. Related: Antiretrovirals.
Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence
3 October 2022. Related: Antiretrovirals, Drug resistance.
Tecovirimat treatment for monkeypox in the UK: importance of the PLATINUM study
3 October 2022. Related: mpox (monkeypox).
Levels of monkeypox viral load in different body sites supports highest risk from body contact
3 October 2022. Related: mpox (monkeypox).
Severe complication of monkeypox reported to the US CDC: risks associated with HIV and other causes of immunosuppression
3 October 2022. Related: mpox (monkeypox).
New reports on MPX vaccine efficacy suggest protection but cases reported after two shots
3 October 2022. Related: mpox (monkeypox).
Other monkeypox studies of interest
3 October 2022. Related: mpox (monkeypox).
BHIVA, BASHH and other professional organisations publish open letters on the refusal by the UK government to acknowledge monkeypox crisis
3 October 2022. Related: mpox (monkeypox).
Reduced HAND prevalence in large cross-sectional cohort study
3 October 2022. Related: Coinfections and complications.
Update to IAS-USA drug resistance tables
3 October 2022. Related: Drug resistance.
HTB: no. 10 (3 October 2022) PDF download
3 October 2022. Related: PDFs.
HTB: no. 9 (3 September 2022) PDF download
1 September 2022. Related: PDFs.
HTB September 2022 (1 September 2022)
1 September 2022. Related: Editorial.
Update on monkeypox in the UK: reduced cases, vaccine access, transmission and treatment…
1 September 2022. Related: Special reports, mpox (monkeypox).
24th International AIDS Conference (AIDS 2022)
1 September 2022. Related: Conference reports.
Dolutegravir no longer linked to higher risk of neural tube defects: latest update from the Tsepamo study
1 September 2022. Related: Conference reports, Pregnancy.
Weight gain with dolutegravir and TAF in ADVANCE study continues out to week 192
1 September 2022. Related: Conference reports, Women's health.
VRC01 added to early ART in infants did not reduce viral reservoir
1 September 2022. Related: Conference reports, Paediatric care.
Using PrEP during pregnancy is safe for children
1 September 2022. Related: Conference reports, Pregnancy, Paediatric care.
Long-acting CAB/RPV injections have a similar weight and lipid profile to dolutegravir-based oral ART
1 September 2022. Related: Conference reports.
Montreal’s response to monkeypox: rapid vaccine rollout, 39 breakthrough infections
1 September 2022. Related: Conference reports, mpox (monkeypox).
Summary of 620 cases of monkeypox seen at three London clinics
1 September 2022. Related: Conference reports, mpox (monkeypox).
Advances in HIV cure-related research: IAS workshop now online
1 September 2022. Related: Conference reports.
Lenacapavir approved in the EU and UK to treat multidrug resistant HIV
1 September 2022. Related: Antiretrovirals.
US survey reports 50% of gay men changed sexual behaviour to avoid monkeypox
1 September 2022. Related: mpox (monkeypox).
US model limits monkeypox infections by one-third from having fewer one-time partners: short-term strategy until next vaccine supply
1 September 2022. Related: mpox (monkeypox).
BHIVA include efficacy data on HIV and monkeypox vaccine: updated statement (August 2022)
1 September 2022. Related: mpox (monkeypox).
Monkeypox DNA detected in anal samples of asymptomatic men in Paris and Belgium
1 September 2022. Related: mpox (monkeypox).
Unusual case reports: non-sexual acquisition, severe MPX and advanced HIV, human-to-dog transmission
1 September 2022. Related: mpox (monkeypox).
Tecovirimat for treating mild monkeypox: new studies open in the UK and US
1 September 2022. Related: mpox (monkeypox).
US cases: MMWR report on 1891 cases to 22 July 2022
1 September 2022. Related: mpox (monkeypox).
Monkeypox transmission in heterosexual couples in Nigeria
1 September 2022. Related: mpox (monkeypox).
Access to vaccines and treatment for pregnant women at risk of monkeypox
1 September 2022. Related: mpox (monkeypox).
MPX DNA easily detected on surfaces in hospital after cleaning
1 September 2022. Related: mpox (monkeypox).